文献速递膀胱癌与上尿路尿路上皮癌泌尿系感染

退伍军人显微镜下血尿的当代评估:癌症检出与资源利用

Contemporary Microhematuria Evaluation in Veterans: Cancer Detection and Resource Utilization.
PubMed 文献 · Urology · 2026-02-20

该研究回顾性分析2021至2024年Jesse Brown退伍军人事务中心1046例显微镜下血尿退伍军人,评估泌尿外科会诊率、膀胱癌检出分布及不同评估策略的估计成本。结果显示71.6%患者接受会诊,但膀胱癌仅在高危组检出7例(0.7%),提高诊断阈值至≥26 RBC/hpf可降低总成本但增加每例评估成本。

要点

  • 退伍军人显微镜下血尿患者泌尿外科会诊率高达71.6%,但膀胱癌检出率仅0.7%。
  • 血尿严重程度或年龄风险分层均不能预测泌尿外科会诊。
  • 提高诊断阈值至≥26 RBC/hpf可降低总成本,但增加每例评估成本。

核心结论

  • 退伍军人显微镜下血尿的泌尿外科评估常见,但膀胱癌检出率低且集中于高危个体。
  • 当前转诊模式可能对低危患者过度使用资源。
  • 提高诊断阈值及以超声替代CT用于低危患者可降低成本。

研究设计与样本

  • 回顾性研究,纳入2021至2024年Jesse Brown退伍军人事务中心1046例显微镜下血尿退伍军人。
  • 按血尿严重程度(低:3-10 RBC/hpf,中:11-25,高:≥26)和年龄(低:18-39岁,中:40-59岁,高:≥60岁)进行风险分层。

主要发现

  • 1046例中71.6%接受泌尿外科会诊。
  • 按血尿风险分层,低危69.5%、中危70.5%、高危75.9%接受会诊。
  • 血尿或年龄风险均不能预测会诊。
  • 高危患者中检出膀胱癌7例(0.7%)。

关键数值与推荐

  • 提高诊断阈值至≥26 RBC/hpf使总成本从$1015,029降至$382,939,但每例评估成本从$971升至$1201。

临床怎么用

  • 对低危显微镜下血尿患者可考虑提高诊断阈值以减少不必要的评估。
  • 低危患者可用超声替代CT以降低资源使用。
  • 需未来多中心研究验证并检查低危患者膀胱镜和影像学的过度使用。

局限性

  • 单中心回顾性研究,结果需多中心验证。
  • 需进一步检查低危患者膀胱镜和影像学的过度使用情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate urologic consultations, bladder cancer (BCa) distribution, and estimated costs of alternative evaluation strategies for microhematuria (MH) at a Veterans Affairs (VA) center. METHODS: We retrospectively studied Veterans with MH at Jesse Brown VA (2021-2024). Patients were risk-stratified by MH severity (low: 3-10 red blood cells per high-powered field [RBC/hpf], intermediate: 11-25, high: ≥26) and age (low: 18-39, intermediate: 40-59, high: ≥60). The primary outcome was urology consultation. BCa detection was assessed across risk groups, and procedural costs compared across guideline-based and alternative strategies. RESULTS: Among 1046 veterans, 71.6% received a urology consult. When stratified by MH-based risk, 69.5% of low-risk, 70.5% of intermediate-risk, and 75.9% of high-risk patients received a consult. Neither MH- nor age-based risk predicted consultation. BCa was detected in 7 high-risk patients (0.7%). Raising the diagnostic threshold to ≥26 RBC/hpf reduced total costs ($382,939 vs $1015,029) but increased costs per patient evaluated ($1201 vs $971). CONCLUSION: Urologic evaluation among Veterans with MH is common, yet BCa detection is low and concentrated in high-risk individuals. Current referral patterns may overuse resources for low-risk patients. Raising diagnostic thresholds and substituting ultrasound for CT in low-risk patients could reduce costs. Future multi-center studies should validate these findings and examine overuse of cystoscopy and imaging for low-risk patients.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Sridalla K, Nicolas JD, Zhao L, et al. Contemporary Microhematuria Evaluation in Veterans: Cancer Detection and Resource Utilization. Urology. 2026. PMID: 41724391. doi:10.1016/j.urology.2026.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。